Immunological Properties of Recombinant Mycobacterium bovis Bacillus Calmette‐Guérin Strain Expressing Fusion Protein IL‐2‐ESAT‐6

The live vaccine Mycobacterium bovis bacillus Calmette‐Guérin (BCG) provides variable efficacy against adult pulmonary tuberculosis (TB). Recombinant BCG, expressing either immunodominant antigens or Th1 cytokines, is a promising strategy for developing a new TB vaccine. However, not much is known about whether the introduction of cytokine and specific antigen genes concurrently into the BCG strain could improve the immunogenicity of BCG. In this study, a recombinant BCG strain (rBCG) expressing the fusion protein human interleukin (IL)‐2 and ESAT‐6 (early secreted antigenic target‐6 kDa) antigen of Mycobacterium tuberculosis was constructed. Six weeks after BALB/c mice (H‐2 d ) were immunized with 10 6 colony forming units (CFUs) BCG or rBCG, splenocyte proliferation was determined with MTT [3‐(4,5‐dimethylthiazolyl‐2)‐2, 5‐diphenyltetrazolium bromide] assay, IL‐4 and interferon (IFN)‐γ produced by splenocytes were tested by enzyme linked immunosorbent assay (ELISA,) and the cytotoxicity of splenocytes from immunized mice to P815 cells (H‐2 d ) expressing ESAT‐6 protein was measured using CytoTox 96 Non‐Radioactive Cytotoxicity Assay. Compared with native BCG‐vaccinated mice, rBCG induced stronger Th1 responses that were confirmed by high lymphoproliferative responses and IFN‐γ production to culture filtrate protein (CFP) or ESAT‐6 protein. Moreover, rBCG induced significant enhanced CTL responses against P815‐ESAT‐6 cells. Results from rBCG‐immunized mice demonstrated that introducing the il‐2 and esat‐6 genes into BCG could enhance Th1 type immune responses to ESAT‐6. Further investigation is needed by introducing other Th1 cytokines and antigens into BCG to optimize the protective efficacy against TB. Edited by Ming‐Hua XU